Effect of Anticoagulant on T-Cell Expression of IL-2R and β Chains
| . | CD4+ T Cells . | CD4− T Cells . | ||||
|---|---|---|---|---|---|---|
| Control IgG1 . | Anti–IL-2R α . | Anti–IL-2R β . | Control IgG1 . | Anti–IL-2R α . | Anti–IL-2R β . | |
| K-EDTA | ||||||
| Whole blood | 0.3 ± 0.2 | 49.6 ± 8.2 | 2.3 ± 1.3 | 0.7 ± 0.6 | 14.5 ± 5.1 | 28.4 ± 13.4 |
| PBMCs | 0.7 ± 0.3 | 49.2 ± 3.5 | 3.3 ± 0.8 | 1.4 ± 1.2 | 15.5 ± 5.6 | 30.8 ± 10.2 |
| Na-heparin | ||||||
| Whole blood | 3.4 ± 6.6 | 49.7 ± 6.3 | 2.7 ± 1.0 | 2.8 ± 4.9 | 15.9 ± 5.3 | 32.2 ± 14.5 |
| PBMCs | 1.0 ± 0.6 | 48.4 ± 5.7 | 3.3 ± 0.4 | 1.3 ± 0.6 | 14.5 ± 3.6 | 30.7 ± 11.9 |
| Na-citrate | ||||||
| Whole blood | 0.3 ± 0.3 | 49.6 ± 7.9 | 2.6 ± 1.0 | 0.9 ± 0.8 | 16.2 ± 6.1 | 31.1 ± 12.6 |
| PBMCs | 0.9 ± 0.5 | 49.7 ± 6.5 | 2.6 ± 0.7 | 1.4 ± 0.7 | 15.3 ± 4.5 | 26.0 ± 8.6 |
| . | CD4+ T Cells . | CD4− T Cells . | ||||
|---|---|---|---|---|---|---|
| Control IgG1 . | Anti–IL-2R α . | Anti–IL-2R β . | Control IgG1 . | Anti–IL-2R α . | Anti–IL-2R β . | |
| K-EDTA | ||||||
| Whole blood | 0.3 ± 0.2 | 49.6 ± 8.2 | 2.3 ± 1.3 | 0.7 ± 0.6 | 14.5 ± 5.1 | 28.4 ± 13.4 |
| PBMCs | 0.7 ± 0.3 | 49.2 ± 3.5 | 3.3 ± 0.8 | 1.4 ± 1.2 | 15.5 ± 5.6 | 30.8 ± 10.2 |
| Na-heparin | ||||||
| Whole blood | 3.4 ± 6.6 | 49.7 ± 6.3 | 2.7 ± 1.0 | 2.8 ± 4.9 | 15.9 ± 5.3 | 32.2 ± 14.5 |
| PBMCs | 1.0 ± 0.6 | 48.4 ± 5.7 | 3.3 ± 0.4 | 1.3 ± 0.6 | 14.5 ± 3.6 | 30.7 ± 11.9 |
| Na-citrate | ||||||
| Whole blood | 0.3 ± 0.3 | 49.6 ± 7.9 | 2.6 ± 1.0 | 0.9 ± 0.8 | 16.2 ± 6.1 | 31.1 ± 12.6 |
| PBMCs | 0.9 ± 0.5 | 49.7 ± 6.5 | 2.6 ± 0.7 | 1.4 ± 0.7 | 15.3 ± 4.5 | 26.0 ± 8.6 |
Values are the percentage of cells within the indicated subset showing a relative fluorescence intensity of greater than 10 after incubation with the indicated monoclonal (mean ± SD).